Zhejiang HISUN Biomaterials Co. Ltd. A (688203) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Zhejiang HISUN Biomaterials Co. Ltd. A stock ¥11.83, price ¥12.47, upside -5.1%, quality 48 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 31, 2026.
How to read this chart
50‑month range ¥7.72 – ¥24.30 · fair‑value band ¥8.31 – ¥16.76 · the ¥12.47 price screens above the ¥11.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 31, 2026.
Follow Zhejiang HISUN Biomaterials Co. Ltd. A in your weekly email
Every Wednesday you see whether Zhejiang HISUN Biomaterials Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Hisun Biomaterials Co.Ltd. engages in the research, development, production, and sale of polylactic acid in China.
Show moreShow less
Its products are used in various applications that include 3D printing, extrusion, thermoforming, film blowing and laminating, injection molding, meltblown non-woven fabric, and injection blow molding. The company was founded in 2004 and is headquartered in Taizhou, China.
Stock analysis
Zhejiang HISUN Biomaterials Co. Ltd. A (688203) currently trades at ¥12.47, while our model-based Fair Value estimate is ¥11.83, so the stock looks roughly fairly valued today (gap 5.4%).
Show more
Valuation
How firm this estimate is: it rests on 16 models at a data quality of 95/100, which puts the data coverage at medium.
Scenario range: ¥8.31 (bear) to ¥16.76 (bull), the price of ¥12.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Zhejiang HISUN Biomaterials Co. Ltd. A reported revenue of 852M CNY in FY2025 versus 585M CNY in FY2021, a compound +9.8%/yr. Reported net income was 9.9M CNY in FY2025, compounding −27.3%/yr from FY2021.
Key figures
Market cap 2.5B CNY (≈ $380M) Small · P/E ratio 73.4 · P/S ratio 2.14 · EPS (TTM) ¥0.1700 · Dividend yield 0.7% · Net margin 2.7% · Return on equity 2.2% · Return on assets (EBIT) 2.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 44% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −36% fair-value upside, at −5%, 688203 screens cheaper than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.6500 to ¥20.77). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥8.31Fair Value ¥11.83Bull¥16.76
Price ¥12.47 · Upside -5.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1421 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−25.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−25.8%
Dividend (yield on the price)0.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 3%
Compare Zhejiang HISUN Biomaterials Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 347 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−5.1% · Above median
Profitability
Return on equity (12 months)2.2% · Below median
Return on assets0.5% · Below median
Net margin (12 months)2.7% · Below median
Operating margin (12 months)8.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)62.8% · Top 25%
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang HISUN Biomaterials Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688203
Frequently asked questions
Is Zhejiang HISUN Biomaterials Co. Ltd. A (688203) overvalued or undervalued?
As of Oct 31, 2026, our model estimates a fair value of ¥11.83 versus a price of ¥12.47, about −5% upside (fairly valued).
What is the fair value of 688203?
Our model-based fair value for Zhejiang HISUN Biomaterials Co. Ltd. A is ¥11.83 (as of Oct 31, 2026), built from audited fundamentals. The current price: ¥12.47.
What is the quality score of 688203?
Zhejiang HISUN Biomaterials Co. Ltd. A has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Our model-based price target is the fair value of ¥11.83 (as of Oct 31, 2026) from 16 valuation models. Cautious scenario ¥8.31, optimistic scenario ¥16.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang HISUN Biomaterials Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥11.83, about −5% upside versus a price of ¥12.47 (fairly valued). Cautious scenario ¥8.31, optimistic scenario ¥16.76. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Zhejiang HISUN Biomaterials Co. Ltd. A reported trailing-twelve-month revenue of about 1.2B CNY (latest available figure, as of Oct 31, 2026).
Does Zhejiang HISUN Biomaterials Co. Ltd. A pay a dividend?
Zhejiang HISUN Biomaterials Co. Ltd. A currently shows a dividend yield of 0.72% relative to its recent price (as of Oct 31, 2026).
What is the intrinsic value of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang HISUN Biomaterials Co. Ltd. A it is ¥11.83 per share (as of Oct 31, 2026), against a price of ¥12.47. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang HISUN Biomaterials Co. Ltd. A stock overvalued or undervalued in 2026?
As of Oct 31, 2026, 688203 trades above its calculated fair value: price ¥12.47, fair value ¥11.83, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688203?
No. The price is what the market pays today (¥12.47); the fair value is what the company's own numbers justify (¥11.83). For Zhejiang HISUN Biomaterials Co. Ltd. A the two are ¥0.6370 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang HISUN Biomaterials Co. Ltd. A worth?
The market values Zhejiang HISUN Biomaterials Co. Ltd. A at about 2.5B CNY (market capitalisation, as of Oct 31, 2026). Per share that is ¥12.47; our models calculate a fair value of ¥11.83 per share.
What do the bullish and bearish scenarios say about 688203?
Our models span a range for Zhejiang HISUN Biomaterials Co. Ltd. A: cautious scenario ¥8.31, base ¥11.83, optimistic ¥16.76 per share (as of Oct 31, 2026, price ¥12.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688203?
Zhejiang HISUN Biomaterials Co. Ltd. A trades at a price-to-earnings ratio of 73.4 (as of Oct 31, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥11.83 is built from several models across several years. Other multiples: P/B 1.7, P/S 2.1, EV/EBITDA 16.4.
How solid is the balance sheet of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Balance-sheet figures for Zhejiang HISUN Biomaterials Co. Ltd. A (as of Oct 31, 2026): return on equity 2.2%, debt of 0.01 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 688203 from its 52-week high?
Zhejiang HISUN Biomaterials Co. Ltd. A trades at ¥12.47, about 49% below its 52-week high of ¥24.30 and 44% above the low of ¥8.68 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.83 is for.
Which stocks are comparable to Zhejiang HISUN Biomaterials Co. Ltd. A?
From the same area (Basic Materials) we also value BASF SE, Dow Inc, Ningxia Baofeng Energy Group, Rongsheng Petrochemical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang HISUN Biomaterials Co. Ltd. A stock attractive at the current price?
The data as of Oct 31, 2026: price ¥12.47, calculated fair value ¥11.83 (−5%), Quality Score 48/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688203 calculated?
We run Zhejiang HISUN Biomaterials Co. Ltd. A through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥11.83, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. Zhejiang HISUN Biomaterials Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The closing price on Oct 30, 2026 was ¥12.47. Our model-based fair value is ¥11.83, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang HISUN Biomaterials Co. Ltd. A right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (¥8.31 to ¥16.76) leaves room in how you read the outcome.
Key figures of Zhejiang HISUN Biomaterials Co. Ltd. A
How large is the market capitalisation of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The market capitalisation of Zhejiang HISUN Biomaterials Co. Ltd. A is 2.5B CNY (≈ $380M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The price-to-sales ratio of Zhejiang HISUN Biomaterials Co. Ltd. A is 2.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Earnings per share at Zhejiang HISUN Biomaterials Co. Ltd. A are ¥0.1700 (price ÷ EPS = P/E 73.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The dividend yield of Zhejiang HISUN Biomaterials Co. Ltd. A is 0.7% (payout 52.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The net margin of Zhejiang HISUN Biomaterials Co. Ltd. A is 2.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The return on equity (ROE) of Zhejiang HISUN Biomaterials Co. Ltd. A is 2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
On an EBIT basis the return on assets of Zhejiang HISUN Biomaterials Co. Ltd. A is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
The operating margin of Zhejiang HISUN Biomaterials Co. Ltd. A is 8.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Revenue at Zhejiang HISUN Biomaterials Co. Ltd. A is growing +62.8% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang HISUN Biomaterials Co. Ltd. A (688203)?
Earnings per share at Zhejiang HISUN Biomaterials Co. Ltd. A are growing +745% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang HISUN Biomaterials Co. Ltd. A (688203) generate?
The free cash flow of Zhejiang HISUN Biomaterials Co. Ltd. A is −106M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zhejiang HISUN Biomaterials Co. Ltd. A (688203) carry?
The net debt of Zhejiang HISUN Biomaterials Co. Ltd. A is 84.0M CNY (fiscal year 2021). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhejiang HISUN Biomaterials Co. Ltd. A in the live analysis
One click puts Zhejiang HISUN Biomaterials Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 31, 2026